AMGN Amgen, Inc.

199.08-4.34 (-2.13%)
Close: August 23, 2019

199.500.42 (+0.21%)
Pre-market

Quote

Previous Close
$199.08
Day Range
$198.01-$203.62
52 Week Range
$166.30-$211.90
Volume
3,400,420
Avg Volume
3,466,979
Dividend TTM
$5.54 (2.78%)
Ex-Dividend Date
2019-08-14

Valuation

Market Cap
$119.39B
Enterprise Value (EV)
$126.62B
PE Ratio
15.66
EV/EBITDA
10.32
Price/Sales
5.13
Price/Book
9.55
PEG Ratio
4.28

Financials

Revenue
$23.77B
Gross Profit
$19.67B
EBITDA
$12.27B
EPS, ttm
$12.71
Profit Margin
35.32%
Revenue/Employee
$1.11M
Next Earnings Date
10/31/2019 (67 days)
Debt to Equity
271%
Debt
$36.53B
Cash
$29.30B
Net Debt
$7.23B

Performance

Beta
0.82
200 Day Moving Avg
$186.85
50 Day Moving Avg
$185.92
52 Week Change
1.24%
YTD Change
1.61%
1 Month Change
13.26%
3 Month Change
16.23%
6 Month Change
4.88%
1 Year Change
1.24%
2 Year Change
8.61%
5 Year Change
57.01%

Share Count

Shares Outstanding
599.7M
Float
598.5M
Restricted Shares
1.2M
Restricted Shares, %
0.21%

Amgen, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Robert A. Bradway

Website: http://www.amgen.com

Description: Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Employees: 21,500